FEMY - Femasys Inc logo

Femasys Inc

FEMY

Femasys Inc. develops diagnostic and therapeutic solutions for women’s healthcare, including products for reproductive issues. Its offerings include FemaSeed for insemination, FemVue for fallopian tube assessment, and FemBloc for permanent birth control.

βš•οΈ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago β†’$11today

Score Overview

1 Year
Score
Net Growth36.83%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth0.27%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score4.6
Net Growth-56.12%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth94.92%
Rev Trend80%
Revenue Consistencyβ€”
All Time
Score
Net Growth-56.12%
Net Trend40%
Net Income Consistency
Rev Growth94.92%
Rev Trend80%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Femasys Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. FEMY does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 1.56β€”
1 Year2025-10-22
$ 11.56-86.51%
5 Years2021-10-22
$ 139.20-98.88%
All Time2021-06-18
$ 240.00-99.35%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 2M-$ 11M$ 1M
2025$ 2M-$ 18M$ 9M
2024$ 1M-$ 18M$ 3M
2023$ 1M-$ 14M$ 21M
2022$ 1M-$ 11M$ 12M
IPO2021$ 1M-$ 7M$ 24M
FEMY - Femasys Inc logo

Femasys Inc fundamental performance

Between 2021 and 2025, revenue grew from $ 1M to $ 2M and net income went from -$ 7M to -$ 18M. Revenue increased in 80% of the years measured; net income in 40%.

Femasys Inc currently holds a 5-year HDB Score of 4.6 out of 10. How the HDB Score is calculated.

Membership

Explore FEMY with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies